Glucocorticoids as a brake on cardiac regenerative factors: a novel therapeutic strategy

We are excited to announce our new publication in Nature Cardiovascular Research, in which we describe an innovative strategy to enhance heart regeneration through blockade of the glucocorticoid receptor.

In our study, we demonstrate that glucocorticoids—steroid hormones that are physiologically present in the circulation—play a key role in limiting the responsiveness of cardiomyocytes to major regenerative growth factors and cytokines. Specifically, we show that these hormones act as a true hormonal brake, contributing to the loss of the heart’s regenerative capacity during late postnatal stages and in adulthood.

A central finding of our work is the demonstration that pharmacological blockade of the glucocorticoid receptor can remove this brake, restoring the ability of cardiomyocytes to respond to proliferative stimuli. This approach substantially enhances the effectiveness of growth factor–based regenerative therapies, even in mature hearts.

In preclinical models, we further observed that the combination of a glucocorticoid receptor antagonist with a regenerative factor produces markedly superior results compared with single treatments. This effect is particularly relevant in settings of cardiac damage associated with anthracycline-based cancer therapies, where the combined approach improved cardiomyocyte survival and preserved cardiac function.

Overall, we believe that these findings open new avenues for the development of combined therapeutic strategies aimed at regenerating cardiac tissue and that, if clinically validated, they could have a significant impact on the treatment of heart failure.

Congratulations to Silvia Da Pra and Stefano Boriati, a postdoctoral researcher and a PhD student in our group, who carried out the majority of the experimental work, and thanks to all team members Carmen Miano, Francesca Sacchi, Chiara Bongiovanni, Irene Del Bono and Nicola Pianca for their contributions. We also thank the collaborators who were instrumental to the success of this project, in particular the research groups led by Eldad Tzahor (Weizmann Institute of Science, Israel), Catherine Wilson (University of Cambridge, United Kingdom), and Mattia Lauriola and Carlo Ventura (University of Bologna, Italy).

Go to the full article: : Da Pra S, Boriati S, Miano M, Sacchi F,  Batho C,  Bongiovanni C, Del Bono I, Aharonov A, Pianca N, Tassinari R, Dahir R, Ventura C, Lauriola M, Tzahor E, Wilson C & D’Uva G. Harnessing glucocorticoid receptor antagonism to enhance the efficacy of cardiac regenerative growth factors and cytokines : Nature Cardiovascular Research 2026

Read-only access to the article (no subscription required): https://rdcu.be/e2EN0

Our review on cardiotoxicity of anticancer therapies is online!

Unfortunately, anticancer drugs can induce side effects on heart tissue. This phenomenon, known as cardiotoxicity, in severe cases, can reduce the quality and life expectancy of cancer patients, regardless of the oncological prognosis.

The good news is that the complex molecular mechanisms responsible for these effects in different classes of anticancer drugs are beginning to emerge, and as a result, potential therapeutic approaches to protect the heart from these effects are beginning to be proposed.

#cardiotossicità #farmaciantitumorali #ricercascientifica #medicina #salute #unibo #irccsmultimedica #conFondazioneCariplo

 

Abstract: Chemotherapy and targeted therapies have significantly improved the prognosis of oncology patients. However, these antineoplastic treatments may also induce adverse cardiovascular effects, which may lead to acute or delayed onset of cardiac dysfunction. These common cardiovascular complications, commonly referred to as cardiotoxicity, not only may require the modification, suspension, or withdrawal of life-saving antineoplastic therapies, with the risk of reducing their efficacy, but can also strongly impact the quality of life and overall survival, regardless of the oncological prognosis. The onset of cardiotoxicity may depend on the class, dose, route, and duration of administration of anticancer drugs, as well as on individual risk factors. Importantly, the cardiotoxic side effects may be reversible, if cardiac function is restored upon discontinuation of the therapy, or irreversible, characterized by injury and loss of cardiac muscle cells. Subclinical myocardial dysfunction induced by anticancer therapies may also subsequently evolve in symptomatic congestive heart failure. Hence, there is an urgent need for cardioprotective therapies to reduce the clinical and subclinical cardiotoxicity onset and progression and to limit the acute or chronic manifestation of cardiac damages. In this review, we summarize the knowledge regarding the cellular and molecular mechanisms contributing to the onset of cardiotoxicity associated with common classes of chemotherapy and targeted therapy drugs. Furthermore, we describe and discuss current and potential strategies to cope with the cardiotoxic side effects as well as cardioprotective preventive approaches that may be useful to flank anticancer therapies.

Go to the original article: Morelli MB, Miano C, Bongiovanni C, Sacchi F, Da Pra S, Lauriola M and D’Uva G. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Frontiers in Cardiovascular Medicine, 2022

D’Uva lab receives Cariplo grant award on cancer and cardiotoxicity

We have just received very good news: we won the research grant “Cariplo – Young Researchers“.
This grant will allow us, in parallel to ongoing studies in the field of cardiac regeneration following a heart attack, to expand our research on cancer and the emerging problem of cardiotoxicity of anticancer therapies.
Cardiotoxicity, i.e. toxic effects on heart function, is responsible for a poor quality of life and reduced survival of cancer patients, regardless of the oncologic prognosis. The aim of our research is to develop innovative strategies to limit these side effects while increasing the efficacy of anti-cancer therapies targeting HER2 (a well-known oncogene also known as ERBB2) in breast cancer patients.
The project is in collaboration with the University of Bologna and Biomedical Research Foundation / University of Turin.
These funds will also give us the opportunity to recruit another researcher into my team. Soon we will post the details.
Happy 2018 to everyone!